A phase I study of the combination of two hypoxic cell radiosensitizers, Ro 03-8799 and SR-2508: Toxicity and pharmacokinetics
- 1 July 1986
- journal article
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 12 (7) , 1113-1116
- https://doi.org/10.1016/0360-3016(86)90238-5
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- A clinical phase I toxicity study of Ro 03–8799: plasma, urine, tumour and normal brain pharmacokineticsThe British Journal of Radiology, 1986
- Cellular Uptake of Misonidazole and Analogues with Acidic or Basic FunctionsInternational Journal of Radiation Biology, 1985
- The clinical testing of Ro 03-8799—Pharmacokinetics, toxicology, tissue and tumor concentrationsInternational Journal of Radiation Oncology*Biology*Physics, 1984
- A phase I study of the hypoxic cell radiosensitizer Ro-03-8799International Journal of Radiation Oncology*Biology*Physics, 1984
- Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508International Journal of Radiation Oncology*Biology*Physics, 1984
- High-performance liquid chromatographic analysis of the new hypoxic cell radiosensitiser, Ro 03-8799, in biological samplesJournal of Chromatography B: Biomedical Sciences and Applications, 1983
- In vivo testing of a 2-nitroimidazole radiosensitizer (Ro 03–8799) using repeated administrationInternational Journal of Radiation Oncology*Biology*Physics, 1982
- Partition Coefficient as a Guide to the Development of Radiosensitizers Which Are Less Toxic Than MisonidazoleRadiation Research, 1980